10-K: Aethlon Medical Reports Fiscal Year 2024 Results, Highlights Progress in Clinical Trials

Aethlon Medical's annual report details ongoing efforts in developing the Hemopurifier for cancer and viral infections, while navigating financial challenges and regulatory hurdles.

Summary

• Aethlon Medical, a clinical-stage company, is focused on developing the Hemopurifier, an immunotherapeutic device targeting cancer and life-threatening viruses.
• The Hemopurifier has received Breakthrough Device designation from the FDA for both advanced cancer and life-threatening viruses.
• The company is preparing for clinical trials in Australia for solid tumors, including head and neck and gastrointestinal cancers, and has received ethics approval for a phase 1 oncology trial at Royal Adelaide Hospital.
• Aethlon has completed an in vitro binding study showing the Hemopurifier removes extracellular vesicles from plasma, supporting planned clinical trials.
• The Hemopurifier has shown in vitro effectiveness against multiple viruses, including HIV, hepatitis-C, Ebola, Zika, and various strains of influenza and coronaviruses.
• A previous COVID-19 study in the US was terminated due to lack of ICU patients, but the IDE remains open, and a COVID-19 trial is ongoing in India.
• The company is also exploring the Hemopurifier's potential in organ transplantation, specifically for removing harmful substances from recovered kidneys.
• Aethlon reported a net loss of $12.2 million for fiscal year 2024, compared to a net loss of $12.0 million in fiscal year 2023.
• Research and development expenses were approximately $2.5 million in fiscal year 2024 and $2.7 million in fiscal year 2023.
• The company had a cash balance of $5.4 million and working capital of $4.4 million as of March 31, 2024.
• Aethlon has raised approximately $4.7 million in gross proceeds from a public offering in May 2024 and an additional $1.8 million from warrant exercises in June 2024.
• There is substantial doubt about the company's ability to continue as a going concern within one year of the date of the financial statements.

Sentiment

Score: 4

Explanation: The document highlights positive progress in clinical trials and regulatory approvals, but the financial situation and going concern warning temper the overall sentiment. The company faces significant financial and operational risks.

Positives

• The Hemopurifier has received FDA Breakthrough Device designation for two independent indications.
• Ethics approval has been granted for a phase 1 oncology trial in Australia.
• The in vitro binding study provides pre-clinical evidence to support planned clinical trials.
• The Hemopurifier has demonstrated in vitro effectiveness against multiple viruses.
• The company has secured additional funding through a public offering and warrant exercises.
• Aethlon has an active COVID-19 trial in India.

Negatives

• Aethlon reported a net loss of $12.2 million for fiscal year 2024.
• The company has substantial doubt about its ability to continue as a going concern within one year.
• A previous COVID-19 study in the US was terminated due to lack of ICU patients.
• The transition to a new supplier for GNA is delayed due to FDA approval requirements.
• The company has limited experience in large-scale manufacturing agreements.
• The company is dependent on single suppliers for some critical components of the Hemopurifier.

Risks

• The company has incurred significant losses and expects to continue to incur losses for the foreseeable future.
• Aethlon will require additional financing to sustain operations, which may dilute existing stockholders.
• Delays, interruptions, or cessation of production by third-party suppliers could impact manufacturing.
• The Hemopurifier technology may become obsolete due to new scientific developments.
• Failure to comply with regulations could delay or prevent commercialization.
• The company may be delisted from the Nasdaq Capital Market if it fails to regain compliance with listing requirements.
• The company may have difficulty attracting and retaining executive management and directors.
• Delays in clinical trials could jeopardize regulatory approval and operations.
• The company faces intense competition in the medical device industry.
• The company has limited experience in the organ transplant market.
• The company is exposed to product liability risks.
• The company may not receive approval from the FDA to market a medical device in the United States.
• The company may not obtain additional U.S. Government contracts to further develop its technology.
• The company's bylaws designate the Eighth Judicial District Court of Clark County, Nevada, as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by its stockholders.
• The company's stock price is speculative and there is a risk of litigation.
• The company's stock price is volatile and there is a risk of not being able to sell shares at or near trading prices.
• The company's issuance of additional shares of common stock or convertible securities could be dilutive.
• The company's officers and directors are entitled to indemnification from the company for liabilities under its articles of incorporation, which could be costly to the company and may discourage the exercise of stockholder rights.
• The company's bylaws and Nevada law may discourage, delay or prevent a change of control of the company or changes in its management, which would have the result of depressing the trading price of its common stock.
• The company incurs substantial costs as a result of being a public company and its management expects to devote substantial time to public company compliance programs.
• If securities or industry analysts do not publish research or reports about the company's business, or if they change their recommendations regarding its stock adversely, its stock price and trading volume could decline.
• The company relies upon licenses and patent rights from third parties which are subject to termination or expiration.
• The company could become subject to intellectual property litigation that could be costly, result in the diversion of management's time and efforts, require the company to pay damages, prevent the company from selling its commercially available products and/or reduce the margins the company may realize from its products.
• The company's ability to use net operating loss carryforwards and certain other tax attributes to offset future taxable income or taxes may be limited.
• The company's use of hazardous materials, chemicals and viruses exposes it to potential liabilities for which it may not have adequate insurance.
• The company's products may in the future be subject to product recalls.
• Even though the company has received breakthrough device designation for the Hemopurifier for two independent indications, this designation may not expedite the development or review of the Hemopurifier and does not provide assurance ultimately of PMA submission or approval by the FDA.
• The company's bylaws designate the Eighth Judicial District Court of Clark County, Nevada, as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by its stockholders, which could limit its stockholders ability to obtain a favorable judicial forum for disputes with the company or its directors, officers, employees or agents.

Future Outlook

Aethlon expects to continue to incur increasing negative cash flows and net losses for the foreseeable future and will need to raise additional capital through equity and/or debt financing. The company plans to continue actively pursuing financing alternatives, however, there can be no assurance that it will obtain the necessary funding.

Management Comments

• The company is monitoring closely the impact of inflation, recent bank failures and the war between Russia and Ukraine and the military conflicts in Israel and the surrounding areas, as well as related political and economic responses and counter-responses by various global factors on our business.
• Given the level of uncertainty regarding the duration and impact of these events on capital markets and the U.S. economy, we are unable to assess the impact on our timelines and future access to capital.

Industry Context

The medical device industry for treating infectious diseases and cancer is highly competitive, with companies facing significant capital and regulatory challenges. Aethlon's Hemopurifier is a clinical-stage device, requiring the establishment of medical industry support through human clinical studies. The company faces competition from well-funded pharmaceutical organizations and other medical device companies.

Comparison to Industry Standards

• Aethlon's financial results, with a net loss of $12.2 million and limited revenue, are not uncommon for a clinical-stage biotechnology company focused on developing novel medical devices.
• Compared to companies like Exthera Medical Corporation, which also produces blood filters, Aethlon is still in the clinical trial phase and has not yet achieved commercialization.
• Many biotechnology companies in the medical device industry, such as those developing cancer therapies, often have similar financial profiles with high R&D expenses and limited revenue until regulatory approval is obtained.
• The company's reliance on single suppliers for critical components is a risk that is not unique to Aethlon, but is a common challenge in the medical device industry.
• The company's cash position of $5.4 million as of March 31, 2024, is relatively low compared to some of its competitors, highlighting the need for additional capital raises.

Management Changes

Related Party Transactions

• The company accrued unpaid fees of $68,250 owed to its non-employee directors.
• The company paid out accrued vacation of $53,076 to its former CEO, Dr. Fisher.
• The company accrued $435,378 for cash severance payments and COBRA payments to be paid monthly over a 12-month period to its former CEO, Dr. Fisher.
• The company recorded $393,139 of stock-based compensation for the acceleration of vesting for 50% of then outstanding options held by Dr. Fisher at the time of his separation from the Company.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity raises and potential loss of investment due to the company's financial challenges.
• Employees may experience uncertainty due to the company's financial instability and potential restructuring.
• Customers (healthcare providers and patients) may face delays in accessing the Hemopurifier due to manufacturing and regulatory hurdles.
• Suppliers may face uncertainty regarding future orders and payments due to the company's financial situation.
• Creditors face the risk of non-payment due to the company's financial instability.

Next Steps

• Continue preparations for clinical trials in Australia for solid tumors.
• Apply to Ethics Committees for additional clinical trial sites in Australia and India.
• Work with the FDA to qualify a second supplier of GNA.
• Continue to monitor the impact of global events on capital markets and the U.S. economy.
• Pursue additional financing alternatives.

Key Dates

Keywords

Hemopurifier, cancer, viral infections, immunotherapy, clinical trials, exosomes, FDA, Breakthrough Device, COVID-19, organ transplantation, GNA, SARS-CoV-2, oncology, regulatory approval, medical device